Curing Rare Diseases Asia begins its act - Verticaltalk Pharma | e-Newsletter | Volume 1 No. 3 | 2006

Pharma Focus Asia - eNewsletter

Verticaltalk Pharma e-Newsletter

Volume 1 No.3 2006

Curing Rare Diseases

Asia begins its act

PFA - Issue March 2006


	Indian pharma to grow at 13.6% from 2006 to 2010

	Wyeth Pharmaceuticals to develop DNA vaccines


	The Convention on Pharmaceutical Ingredients, Mumbai, India From Dec 01 -Dec 03 '06

	MAHATech 2006, Mumbai, India From Dec 22 -Dec 25 '06

Pharma Press Releases


	Advinus Therapeutics and Merck establish drug discovery and development collaboration

	Novartis creates new strategic biomedical R&D center in Shanghai

Current Issue \| Archives \| Advertise
In this issue of The Pharma Edge
Orphan Drugs Psyche of Japanese Consumers Contract Manufacturing Strategies Outsourcing R&D	Tapping China and India for Biopharma Pharmacovigilance Ethics and the Pharmaceutical Industry Pharma News

Orphan Drugs - Asia, The New Frontier
By Mary Dunkle, Vice President of Communications, National Organization for Rare Disorders, US

As the home to more than half the world’s population, Asia is poised to become an area of tremendous interest to pharmaceutical and biotechnology companies engaged in research on the thousands of diseases considered rare. Asian countries are patterning their orphan drug policies on the United States’ Orphan Drug Act of 1983, which provides seven years of marketing exclusivity and other financial incentives for companies that develop products for rare diseases.

Understanding the Psyche of Japanese Pharmaceutical Consumers
By Yuta Kaneko, Director, Meditech, ACNielsen, Japan

Understanding the psyche of Japanese pharmaceutical consumers is really a case of understanding the psyche of older and elderly Japanese. An aging society with strong expectations for longevity has created a substantial segment of frequent pharmacy users, with growing concerns about their health, and their ability to attract the attention of government and industry to address them. The needs of Japanese pharmaceutical consumers for more and better therapies are on a collision course with efforts by the government to reduce healthcare costs.

Pharma Bookshelf

Ethics and the Pharmaceutical Industry
Authors: Michael A. Santoro, Thomas M. Gorrie

Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior.

Outsourcing R&D in the Pharmaceutical Industry
Author: Bianca Piachaud
This book examines the strategic aspects of outsourcing in relation to the firm. It provides a hollstic view of the outsourcing process, starting with conceptualisation, through to implementation and management of the process. Although the book is based on a case study of the pharmaceutical industry, the general principles derived from the Strategic Sourcing Model are generic in nature and the model can be applied to instances of outsourcing in other industries.

Research Insights

Pharmacovigilance Program to Monitor Adverse Reactions of Recombinant Streptokinase in Acute Myocardial Infarction

Streptokinase (SK) is an effective fibrinolytic agent for the treatment of acute myocardial infarction (AMI). The objective of the present study was to assess the adverse drug reactions (ADRs) associated with intravenous recombinant SK in patients with AMI in routine clinical practice. A national, prospective and spontaneous reporting-based pharmacovigilance program was conducted in Cuba. Patient demographics, suspected ADR description, elements to define causality, and outcomes were documented and analyzed.

Projects

TechnoTrends

Industry Reports

GlaxoSmithKline’s New R&D Plant in Singapore GlaxoSmithKline is investing US$ 115 million in a new R&D pilot plant at its Global Manufacturing Supply site in Jurong, Singapore. The new plant, which commenced its construction in 2005 is scheduled to become operational in 2007.

New Technology for Determining the Cardiac Safety Profile of Drugs To help the pharmaceutical industry better understand the cardiac safety profile of the drugs a new technology has been launched consisting of a software called ‘COMPAS’ (Comprehensive Analysis of Repolarisation Signal) and unique ECG Biometrics.

Looking Eastward - Tapping China and India to Reinvigorate the Global Biopharmaceutical Industry The Boston Consulting Group

Pharmaceutical Outsourcing Part 1: An Introduction to Contract Manufacturing Strategies Datamonitor



You are receiving this email because you are either a registered member or requested for a newsletter from Verticaltalk Pharma. To SUBSCRIBE QUESTIONS: For questions or assistance, please contact our Customer Support Staff : verticaltalkpharma@ochre-media.com PRIVACY: View our Privacy Policy Copyright © 2008 Ochre Media Private Limited. All rights reserved.